DR REDDY: Momentum Pauses Amid USFDA Inspection Updates

As on 15 Dec 2025,

was trading largely flat till around 2:15 PM on Monday, marginally up about 0.05% and hovering close to Friday’s closing level. The stock appeared to pause its recent momentum as markets digested regulatory developments. The United States Food & Drug Administration (USFDA) completed a GMP and Pre-Approval Inspection (PAI) at the company’s formulations facility (FTO-SEZ PU01) in Srikakulam, Andhra Pradesh, conducted between December 4–12, and issued a Form 483 with five observations. Notably, the stock had advanced for the last three consecutive sessions, while earlier, from December 4, it closed negative for four straight sessions amid inspection-related caution. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. AI may have been used for grammatical and sentence-structure refinement. Please consult a SEBI-registered advisor before making any investment decisions.